CN116003577B - 一种用于皮肤舒缓修复的重组胶原蛋白及其应用 - Google Patents

一种用于皮肤舒缓修复的重组胶原蛋白及其应用 Download PDF

Info

Publication number: CN116003577B
Authority: CN; China
Prior art keywords: soothing; composition; inclusion; skin; repair
Prior art date: 2023-02-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

CN202310123476.3A

Other languages

English (en)

Chinese (zh)

Other versions

CN116003577A (zh

Inventor

孙怀庆

郭朝万

刘涵

王宁

聂艳峰

肖湲

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Guangdong Marubi Biological Technology Co Ltd

Original Assignee

Guangdong Marubi Biological Technology Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2023-02-14

Filing date

2023-02-14

Publication date

2023-10-31

2023-02-14 Application filed by Guangdong Marubi Biological Technology Co Ltd filed Critical Guangdong Marubi Biological Technology Co Ltd

2023-02-14 Priority to CN202310123476.3A priority Critical patent/CN116003577B/zh

2023-04-25 Publication of CN116003577A publication Critical patent/CN116003577A/zh

2023-06-30 Priority to JP2023108556A priority patent/JP7601957B2/ja

2023-10-31 Application granted granted Critical

2023-10-31 Publication of CN116003577B publication Critical patent/CN116003577B/zh

Status Active legal-status Critical Current

2043-02-14 Anticipated expiration legal-status Critical

Links

102000008186 Collagen Human genes 0.000 title claims abstract description 84
108010035532 Collagen Proteins 0.000 title claims abstract description 84
229920001436 collagen Polymers 0.000 title claims abstract description 81
230000000694 effects Effects 0.000 claims abstract description 79
230000008439 repair process Effects 0.000 claims abstract description 55
239000002773 nucleotide Substances 0.000 claims abstract description 7
125000003729 nucleotide group Chemical group 0.000 claims abstract description 7
229920002305 Schizophyllan Polymers 0.000 claims description 64
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 58
238000002360 preparation method Methods 0.000 claims description 47
WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 claims description 46
239000000203 mixture Substances 0.000 claims description 39
238000011282 treatment Methods 0.000 claims description 31
229920001282 polysaccharide Polymers 0.000 claims description 23
239000005017 polysaccharide Substances 0.000 claims description 23
238000000855 fermentation Methods 0.000 claims description 22
230000004151 fermentation Effects 0.000 claims description 22
235000011187 glycerol Nutrition 0.000 claims description 22
239000000463 material Substances 0.000 claims description 17
238000000034 method Methods 0.000 claims description 12
239000001963 growth medium Substances 0.000 claims description 10
239000003094 microcapsule Substances 0.000 claims description 10
230000005684 electric field Effects 0.000 claims description 9
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
239000003906 humectant Substances 0.000 claims description 8
108090000623 proteins and genes Proteins 0.000 claims description 8
102000004169 proteins and genes Human genes 0.000 claims description 8
229920002385 Sodium hyaluronate Polymers 0.000 claims description 6
239000002736 nonionic surfactant Substances 0.000 claims description 6
229940010747 sodium hyaluronate Drugs 0.000 claims description 6
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 6
150000004676 glycans Chemical class 0.000 claims description 5
238000002156 mixing Methods 0.000 claims description 5
241000222480 Schizophyllum Species 0.000 claims description 4
235000019437 butane-1,3-diol Nutrition 0.000 claims description 4
238000012258 culturing Methods 0.000 claims description 4
239000001534 FEMA 4201 Substances 0.000 claims description 2
ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 claims description 2
229940044176 ceramide 3 Drugs 0.000 claims description 2
229940097941 polyglyceryl-10 laurate Drugs 0.000 claims description 2
229940058015 1,3-butylene glycol Drugs 0.000 claims 1
229960005150 glycerol Drugs 0.000 claims 1
230000004663 cell proliferation Effects 0.000 abstract description 15
230000003020 moisturizing effect Effects 0.000 abstract description 12
150000001413 amino acids Chemical class 0.000 abstract description 10
230000003647 oxidation Effects 0.000 abstract description 9
238000007254 oxidation reaction Methods 0.000 abstract description 9
230000001737 promoting effect Effects 0.000 abstract description 8
230000032683 aging Effects 0.000 abstract description 5
102000012422 Collagen Type I Human genes 0.000 abstract description 4
108010022452 Collagen Type I Proteins 0.000 abstract description 4
102000001187 Collagen Type III Human genes 0.000 abstract description 4
108010069502 Collagen Type III Proteins 0.000 abstract description 4
231100000245 skin permeability Toxicity 0.000 abstract description 3
230000001502 supplementing effect Effects 0.000 abstract description 3
125000003275 alpha amino acid group Chemical group 0.000 abstract 1
210000003491 skin Anatomy 0.000 description 57
230000000052 comparative effect Effects 0.000 description 34
239000000243 solution Substances 0.000 description 21
-1 tissue engineering Substances 0.000 description 19
238000012360 testing method Methods 0.000 description 17
239000000047 product Substances 0.000 description 14
208000003251 Pruritus Diseases 0.000 description 13
239000002994 raw material Substances 0.000 description 13
239000000843 powder Substances 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
244000046146 Pueraria lobata Species 0.000 description 11
235000010575 Pueraria lobata Nutrition 0.000 description 11
210000004027 cell Anatomy 0.000 description 10
HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 10
239000002609 medium Substances 0.000 description 8
239000013589 supplement Substances 0.000 description 8
241000700198 Cavia Species 0.000 description 6
238000002835 absorbance Methods 0.000 description 6
230000008859 change Effects 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
230000007803 itching Effects 0.000 description 6
229940094541 polyglycerin-10 Drugs 0.000 description 6
POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 5
229960001660 histamine phosphate Drugs 0.000 description 5
ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 5
229940070765 laurate Drugs 0.000 description 5
230000002195 synergetic effect Effects 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
241000222481 Schizophyllum commune Species 0.000 description 4
208000028990 Skin injury Diseases 0.000 description 4
230000003064 anti-oxidating effect Effects 0.000 description 4
230000003078 antioxidant effect Effects 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
210000000548 hind-foot Anatomy 0.000 description 4
239000011259 mixed solution Substances 0.000 description 4
230000005855 radiation Effects 0.000 description 4
241000700199 Cavia porcellus Species 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
230000006378 damage Effects 0.000 description 3
239000008367 deionised water Substances 0.000 description 3
229910021641 deionized water Inorganic materials 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
210000003000 inclusion body Anatomy 0.000 description 3
239000007788 liquid Substances 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
239000013598 vector Substances 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000002146 bilateral effect Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000002537 cosmetic Substances 0.000 description 2
230000007547 defect Effects 0.000 description 2
238000001914 filtration Methods 0.000 description 2
238000007710 freezing Methods 0.000 description 2
230000008014 freezing Effects 0.000 description 2
230000006870 function Effects 0.000 description 2
229930027917 kanamycin Natural products 0.000 description 2
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
229960000318 kanamycin Drugs 0.000 description 2
229930182823 kanamycin A Natural products 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
229940049964 oleate Drugs 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
238000004321 preservation Methods 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
FYGDTMLNYKFZSV-WFYNLLPOSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,3s,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-WFYNLLPOSA-N 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
229920002498 Beta-glucan Polymers 0.000 description 1
241001474374 Blennius Species 0.000 description 1
102400000888 Cholecystokinin-8 Human genes 0.000 description 1
101800005151 Cholecystokinin-8 Proteins 0.000 description 1
208000014085 Chronic respiratory disease Diseases 0.000 description 1
208000032544 Cicatrix Diseases 0.000 description 1
102000004266 Collagen Type IV Human genes 0.000 description 1
108010042086 Collagen Type IV Proteins 0.000 description 1
102000009736 Collagen Type XI Human genes 0.000 description 1
108010034789 Collagen Type XI Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
244000137852 Petrea volubilis Species 0.000 description 1
206010040914 Skin reaction Diseases 0.000 description 1
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
241001052560 Thallis Species 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
239000000654 additive Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
230000003712 anti-aging effect Effects 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
239000012539 chromatography resin Substances 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
238000004042 decolorization Methods 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
238000007865 diluting Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003480 eluent Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000005187 foaming Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
210000002683 foot Anatomy 0.000 description 1
230000002431 foraging effect Effects 0.000 description 1
210000000245 forearm Anatomy 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
229960001031 glucose Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229960000789 guanidine hydrochloride Drugs 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
239000000413 hydrolysate Substances 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000000774 hypoallergenic effect Effects 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
230000007365 immunoregulation Effects 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000007373 indentation Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
230000003859 lipid peroxidation Effects 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000006996 mental state Effects 0.000 description 1
230000007102 metabolic function Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
238000009781 safety test method Methods 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
230000037387 scars Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
230000008591 skin barrier function Effects 0.000 description 1
230000035483 skin reaction Effects 0.000 description 1
231100000430 skin reaction Toxicity 0.000 description 1
239000007787 solid Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000010998 test method Methods 0.000 description 1
229910001428 transition metal ion Inorganic materials 0.000 description 1
230000014616 translation Effects 0.000 description 1
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
238000000870 ultraviolet spectroscopy Methods 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
230000037303 wrinkles Effects 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1

Landscapes

Cosmetics (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CN202310123476.3A 2023-02-14 2023-02-14 一种用于皮肤舒缓修复的重组胶原蛋白及其应用 Active CN116003577B (zh)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
CN202310123476.3A CN116003577B (zh)	2023-02-14	2023-02-14	一种用于皮肤舒缓修复的重组胶原蛋白及其应用
JP2023108556A JP7601957B2 (ja)	2023-02-14	2023-06-30	皮膚の鎮静・修復用の組換えコラーゲンおよびその使用

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CN202310123476.3A CN116003577B (zh)	2023-02-14	2023-02-14	一种用于皮肤舒缓修复的重组胶原蛋白及其应用

Publications (2)

Publication Number	Publication Date
CN116003577A CN116003577A (zh)	2023-04-25
CN116003577B true CN116003577B (zh)	2023-10-31

Family

ID=86030055

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN202310123476.3A Active CN116003577B (zh)	2023-02-14	2023-02-14	一种用于皮肤舒缓修复的重组胶原蛋白及其应用

Country Status (2)

Country	Link
JP (1)	JP7601957B2 (ja)
CN (1)	CN116003577B (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN117598926A (zh) *	2023-11-29	2024-02-27	广东丸美生物技术股份有限公司	一种含有重组胶原蛋白的肌肤屏障修复组合物及其应用
CN117481996B (zh) *	2023-11-29	2024-06-18	广东丸美生物技术股份有限公司	一种含有重组胶原蛋白的温和抗老化组合物及其应用
CN117503658B (zh) *	2023-12-05	2024-06-18	广东丸美生物技术股份有限公司	一种含有重组胶原蛋白的多效组合物及其制备方法和应用
CN117815440A (zh) *	2023-12-29	2024-04-05	广东丸美生物技术股份有限公司	一种含重组胶原蛋白的修复消炎保湿组合物及其应用

Citations (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6391288B1 (en) *	1999-07-27	2002-05-21	Shiseido Co., Ltd.	Microcapsule and method of making the same
CN101559041A (zh) *	2009-05-19	2009-10-21	中国科学院过程工程研究所	粒径均一的多肽药物缓释微球或微囊制剂及制备方法
CN102755272A (zh) *	2012-07-20	2012-10-31	澳宝化妆品（惠州）有限公司	一种多效滋润护肤组合物
CN103932969A (zh) *	2014-04-16	2014-07-23	法国奢蔻化妆品有限公司	深海鱼皮胶原蛋白肽抗衰紧肤光亮保湿化妆品及制备方法
CN104161715A (zh) *	2014-06-26	2014-11-26	吴雪琴	一种美白护肤乳液的制备方法及制品
CN105963257A (zh) *	2016-04-26	2016-09-28	广州帝奇医药技术有限公司	一种缓释微粒的制备方法
CN109481326A (zh) *	2018-11-19	2019-03-19	珠海伊斯佳科技股份有限公司	一种晒后修复精华液
CN111944057A (zh) *	2020-07-23	2020-11-17	广州启妆生物科技有限公司	一种重组人胶原蛋白肽及其应用
CN112370489A (zh) *	2020-11-21	2021-02-19	陕西远志医药生物工程有限公司	一种还原女性生态平衡的抑菌凝胶及其制备方法
CN112842944A (zh) *	2021-03-19	2021-05-28	唐发彬	一种基于抗衰老胶原蛋白的化妆品
CN114288389A (zh) *	2021-12-07	2022-04-08	尚诚怡美(成都)生物科技有限公司	一种抗酶解胶原蛋白复合物及其应用
CN114306125A (zh) *	2021-12-27	2022-04-12	广东丸美生物技术股份有限公司	一种含不同分子量裂褶多糖的组合物及其制备方法和应用
CN114404307A (zh) *	2021-12-17	2022-04-29	广东丸美生物技术股份有限公司	一种精氨酸/赖氨酸多肽微囊包裹体及其制备方法和应用
CN114652636A (zh) *	2022-03-10	2022-06-24	广东丸美生物技术股份有限公司	一种抗皱修复组合物及其制备方法和包含该组合物的化妆品
CN115006322A (zh) *	2022-06-06	2022-09-06	广东丸美生物技术股份有限公司	兼具即时和长效的多功效眼膜的配方及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100753472B1 (ko)	2002-03-15	2007-08-31	주식회사 엘지생활건강	사람 콜라겐 ⅰ형의 ｃ-말단에서 유래된 펩타이드에ｔａｔ 펩타이드가 결합된 융합 펩타이드, 이의 제조방법,및 이를 포함하는 피부주름개선 화장료 조성물
CN103102407B (zh)	2013-01-29	2014-04-30	李鹏	基因重组人胶原蛋白
CN111363029B (zh)	2018-12-25	2022-07-12	江苏江山聚源生物技术有限公司	重组人源ⅲ型胶原蛋白、表达菌株及其构建方法
CN113880941B (zh)	2020-07-03	2023-11-28	江苏江山聚源生物技术有限公司	重组人源IxIII胶原蛋白、表达菌株及其应用

2023
- 2023-02-14 CN CN202310123476.3A patent/CN116003577B/zh active Active
- 2023-06-30 JP JP2023108556A patent/JP7601957B2/ja active Active

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6391288B1 (en) *	1999-07-27	2002-05-21	Shiseido Co., Ltd.	Microcapsule and method of making the same
CN101559041A (zh) *	2009-05-19	2009-10-21	中国科学院过程工程研究所	粒径均一的多肽药物缓释微球或微囊制剂及制备方法
CN102755272A (zh) *	2012-07-20	2012-10-31	澳宝化妆品（惠州）有限公司	一种多效滋润护肤组合物
CN103932969A (zh) *	2014-04-16	2014-07-23	法国奢蔻化妆品有限公司	深海鱼皮胶原蛋白肽抗衰紧肤光亮保湿化妆品及制备方法
CN104161715A (zh) *	2014-06-26	2014-11-26	吴雪琴	一种美白护肤乳液的制备方法及制品
CN105963257A (zh) *	2016-04-26	2016-09-28	广州帝奇医药技术有限公司	一种缓释微粒的制备方法
CN109481326A (zh) *	2018-11-19	2019-03-19	珠海伊斯佳科技股份有限公司	一种晒后修复精华液
CN111944057A (zh) *	2020-07-23	2020-11-17	广州启妆生物科技有限公司	一种重组人胶原蛋白肽及其应用
CN112370489A (zh) *	2020-11-21	2021-02-19	陕西远志医药生物工程有限公司	一种还原女性生态平衡的抑菌凝胶及其制备方法
CN112842944A (zh) *	2021-03-19	2021-05-28	唐发彬	一种基于抗衰老胶原蛋白的化妆品
CN114288389A (zh) *	2021-12-07	2022-04-08	尚诚怡美(成都)生物科技有限公司	一种抗酶解胶原蛋白复合物及其应用
CN114404307A (zh) *	2021-12-17	2022-04-29	广东丸美生物技术股份有限公司	一种精氨酸/赖氨酸多肽微囊包裹体及其制备方法和应用
CN114306125A (zh) *	2021-12-27	2022-04-12	广东丸美生物技术股份有限公司	一种含不同分子量裂褶多糖的组合物及其制备方法和应用
CN114652636A (zh) *	2022-03-10	2022-06-24	广东丸美生物技术股份有限公司	一种抗皱修复组合物及其制备方法和包含该组合物的化妆品
CN115006322A (zh) *	2022-06-06	2022-09-06	广东丸美生物技术股份有限公司	兼具即时和长效的多功效眼膜的配方及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Enhanced exopolysaccharide yield and antioxidant activities of Schizophyllum commune fermented products by the addition of Radix Puerariae;Yongfei Deng等;《RSC Adv.》;第38219-38234 *
裂褶多糖保湿功效评价;张琪等;《中国食品学报》;第223-228页 *

Also Published As

Publication number	Publication date
JP7601957B2 (ja)	2024-12-17
JP2024115499A (ja)	2024-08-26
CN116003577A (zh)	2023-04-25

Publication	Publication Date	Title
CN116003577B (zh)	2023-10-31	一种用于皮肤舒缓修复的重组胶原蛋白及其应用
CN107595724B (zh)	2019-09-13	护肤基质及其制备方法与包括其的化妆品
CN113786362B (zh)	2023-07-07	一种具有舒缓平衡护肤功效的化妆水组合物及其制备方法
CN117414312B (zh)	2024-03-19	一种具有修护舒缓功效的水解小核菌胶的制备方法及其应用
CN109998937B (zh)	2021-06-29	含有甘油葡糖苷(αGG)的系列化妆品及其制备方法
CN115317417A (zh)	2022-11-11	一种含愈创木提取物的修护痘敏肌的组合物及其护肤品
CN111840176A (zh)	2020-10-30	一种具有抗糖基化、美白、祛斑、祛皱作用的美容组合物及其应用
CN109453051B (zh)	2020-07-10	一种美白修复面膜及其制备方法
CN117223860A (zh)	2023-12-15	一种抗衰老肽组合物及其制备方法
CN109453090A (zh)	2019-03-12	一种保湿美白、紧致提升的精华液组合物及其制备方法
EP0531978A2 (en)	1993-03-17	Promotor for biological hyaluronic acid synthesis, composition externally applied to the skin and use thereof
CN101249059A (zh)	2008-08-27	一种保湿面膜及其制备方法
CN114099393B (zh)	2024-04-05	一种具有紧致与抗衰功效的组合物及其制备方法和应用
CN107837223B (zh)	2021-05-18	一种含有铁皮石斛提取物的面膜精华液和面膜以及制备方法和应用
KR20150081892A (ko)	2015-07-15	돼지감자 추출물을 함유하는 화장료 조성물
CN112137895A (zh)	2020-12-29	一种含银耳多糖的眼膜及其制备方法
CN111643392A (zh)	2020-09-11	一种具有多效美白抗敏作用的生物寡肽精华液及其制备方法
CN111281844A (zh)	2020-06-16	一种复方天然萃取物淡斑面膜及其制备方法
CN117257703A (zh)	2023-12-22	一种不含化学美白剂的美白组份
KR102381645B1 (ko)	2022-04-01	복령발효추출물을 포함하는 화장료 조성물
CN114272165B (zh)	2024-01-16	美白紧致植物精华护肤乳液及其制备方法
KR20180082058A (ko)	2018-07-18	천연 복합 추출물을 유효성분으로 포함하는 각질 박리용 화장료 조성물
CN109692142B (zh)	2022-01-04	一种茯苓洁面乳及其制备方法
CN109453104B (zh)	2021-05-07	淡斑爽肤精华液及其制备工艺
KR20180124438A (ko)	2018-11-21	아쿠아포린-3 발현촉진 및 항염증 효과를 나타내는 올리고 히알루론산 함유 화장료 조성물

Legal Events

Date	Code	Title
2023-04-25	PB01	Publication
2023-04-25	PB01	Publication
2023-05-12	SE01	Entry into force of request for substantive examination
2023-05-12	SE01	Entry into force of request for substantive examination
2023-10-31	GR01	Patent grant
2023-10-31	GR01	Patent grant